Claudia Diniz Lopes Marques

Claudia Diniz Lopes Marques

Auto-generated profile, based on publicly available information

Claudia Diniz Lopes Marques

Universidade Federal de Pernambuco – UFPE, Recife, Brasil

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2015 in PPAR Research
Verified
Journal Article
Open access
PDF file
ADAndréa Tavares Dantas
Andréa Tavares Dantas
MPMichelly Cristiny Pereira
Michelly Cristiny Pereira
MRMoacyr Rêgo
Moacyr Rêgo
LRLaurindo Ferreira da Rocha
Laurindo Ferreira da Rocha
IPIvan da Rocha Pitta
Ivan da Rocha Pitta
MPMaira Galdino da Rocha Pitta
Maira Galdino da Rocha Pitta
Fibrosis is recognized as an important feature of many chronic diseases, such as systemic sclerosis (SSc), an autoimmune disease of unknown etiology, characterized by immune dysregulation and vascular injury, followed by progressive fibrosis affecting the skin and multiple internal organs. SSc has a poor prognosis because no therapy has been shown to reverse or arrest the progression of fibrosis, representing a major unmet medical need. Recently, antifibrotic effects of PPARγligands have been studiedin vitroandin vivoand some theories have emerged leading to new insights. Aberrant PPARγfunction seems to be implicated in pathological fibrosis in the skin and lungs. This antifibrotic effect is mainly related to the inhibition of TGF-β/Smad signal transduction but other pathways can be involved. This review focused on recent studies that identified PPARγas an important novel pathway with critical roles in regulating connective tissue homeostasis, with emphasis on skin and lung fibrosis and its role on systemic sclerosis.

28 January 2021 in RMD Open
Verified
Journal Article
Open access
PDF file
CMClaudia Diniz Lopes Marques
Claudia Diniz Lopes Marques
AKAdriana Maria Kakehasi
Adriana Maria Kakehasi
MPMarcelo Medeiros Pinheiro
Marcelo Medeiros Pinheiro
LMLicia Maria Henrique Mota
Licia Maria Henrique Mota
CACleandro Pires Albuquerque
Cleandro Pires Albuquerque
ARAna Paula Monteiro Gomides Reis
Ana Paula Monteiro Gomides Reis
Objectives To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. Methods Analysis of the first 8 weeks of observational multicentre prospective cohort study (ReumaCoV Brasil register). Patients with IMRD and COVID-19 according to the Ministry of Health criteria were classified as eligible for the study. Results 334 participants were enrolled, a majority of them women, with a median age of 45 years; systemic lupus erythematosus (32.9%) was the most frequent IMRD. Emergency care was required in 160 patients, 33.0% were hospitalised, 15.0% were admitted to the ICU and 10.5% underwent mechanical ventilation; 28 patients (8.4%) died. In the multivariate adjustment model for emergency care, diabetes (prevalence ratio, PR 1.38; 95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) (PR 1.49; 95% CI 1.21 to 1.85; p50 years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 1.16 to 5.45; p=0.004) and methylprednisolone pulse therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; p<0.001) and pulse therapy with methylprednisolone (PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two variables associated with death were pulse therapy with methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 1.59 to 5.14; p50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process.

1 April 2011 in Revista Brasileira de Reumatologia
Verified
Journal Article
Open access
PDF file
ALAlice Abath Leite
Alice Abath Leite
ACAline Jurema Gesteira Costa
Aline Jurema Gesteira Costa
BLBeatriz de Arruda Matheos de Lima
Beatriz de Arruda Matheos de Lima
APAdriana Valentina Lopes Padilha
Adriana Valentina Lopes Padilha
EAEmidio Cavalcanti de Albuquerque
Emidio Cavalcanti de Albuquerque
CMClaudia Diniz Lopes Marques
Claudia Diniz Lopes Marques
INTRODUÇÃO: Uma vez que a prevalência da osteoartrite (OA) aumenta com o envelhecimento, é comum a coexistência de outras doenças crônicas. OBJETIVOS: Avaliar a frequência de comorbidades em pacientes com OA e mensurar o impacto destas na dor e a função física nesses pacientes. MÉTODOS: Estudo transversal em pacientes portadores de OA do ambulatório de reumatologia do IMIP. A dor foi mensurada pela Escala Visual Analógica (EVA) e a função física pelos índices de Lequesne e SACRAH. Foi realizado um screening para depressão, além de aferição de medidas antropométricas, pressão arterial, dosagem da glicemia de jejum e perfil lipídico. RESULTADOS: Foram estudados 91 pacientes, com média de idade de 59,3 anos, sendo 91,4% do sexo feminino. A frequência de síndrome metabólica foi de 54,9%. Hipertensão arterial sistêmica ocorreu em 75,8% dos casos, dislipidemia em 52,6% e obesidade em 57,1%. O screening para depressão foi positivo em 61,3% dos pacientes. Quando comparamos individualmente os componentes da síndrome metabólica, observamos que pacientes com hipertensão apresentavam maiores escores no SACRAH com diferença estatisticamente significante (P = 0,035). Para as outras variáveis, não foram demonstradas diferenças entre os escores Lequesne, SACRAH e EVA. CONCLUSÃO: Foi observada uma alta frequência de depressão, síndrome metabólica e de seus componentes isoladamente nesse grupo de pacientes com OA, podendo haver impacto da presença destes na dor e na função física desses pacientes. Tais resultados demonstraram a necessidade de investigação e tratamento dessas comorbidades em pacientes com OA. INTRODUCTION: As the prevalence of osteoarthritis (OA) increases with age, the coexistence of other chronic diseases is common. OBJECTIVES: To evaluate the frequency of comorbidities in OA patients and to measure their impact on pain and physical function of those patients. METHODS: Cross-sectional study in OA patients of a public rheumatology clinic. Pain was measured by use of the Visual Analogue Scale (VAS) and physical function by use of the Lequesne's and SACRAH indices. A screening for depression was performed, as were the following measurements: anthropometric data; blood pressure; fasting glycemia; and lipid profile. RESULTS: The study assessed 91 patients (mean age 59.3 years; 91.4% female). The metabolic syndrome frequency was 54.9%. Hypertension occurred in 75.8% of the patients, dyslipidemia in 52.6%, and obesity in 57.1%. The screening for depression was positive in 61.3% of patients. When comparing the metabolic syndrome components individually, patients with hypertension had higher SACRAH scores, with statistically significant differences (P = 0.035). For the other variables, no differences among the Lequesne's, SACRAH and VAS scores were observed. CONCLUSION: This group of OA patients showed a high frequency of depression, metabolic syndrome and its components in isolation, which can impact the pain and physical function of those patients. Such results showed the need for investigating and treating those comorbidities in OA patients

1 January 2017 in Revista Brasileira de Reumatologia (English Edition)
Verified
Journal Article
Open access
CMClaudia Diniz Lopes Marques
Claudia Diniz Lopes Marques
ADAngela Luzia Branco Pinto Duarte
Angela Luzia Branco Pinto Duarte
ARAline Ranzolin
Aline Ranzolin
ADAndrea Tavares Dantas
Andrea Tavares Dantas
NCNara Gualberto Cavalcanti
Nara Gualberto Cavalcanti
GCGeorges Christopoulos
Georges Christopoulos
Chikungunya fever has become a relevant public health problem in countries where epidemics occur. Until 2013, only imported cases occurred in the Americas, but in October of that year, the first cases were reported in Saint Marin island in the Caribbean. The first autochthonous cases were confirmed in Brazil in September 2014; until epidemiological week 37 of 2016, 236,287 probable cases of infection with Chikungunya virus had been registered, 116,523 of which had serological confirmation. Environmental changes caused by humans, disorderly urban growth and an ever-increasing number of international travelers were described as the factors responsible for the emergence of large-scale epidemics. Clinically characterized by fever and joint pain in the acute stage, approximately half of patients progress to the chronic stage (beyond 3 months), which is accompanied by persistent and disabling pain. The aim of the present study was to formulate recommendations for the diagnosis and treatment of Chikungunya fever in Brazil. A literature review was performed in the MEDLINE, SciELO and PubMed databases to ground the decisions for recommendations. The degree of concordance among experts was established through the Delphi method, involving 2 in-person meetings and several online voting rounds. In total, 25 recommendations were formulated and divided into 3 thematic groups: (1) clinical, laboratory and imaging diagnosis; (2) special situations; and (3) treatment. The first 2 themes are presented in part 1, and treatment is presented in part 2.

1 August 2020 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
CMClaudia Diniz Lopes Marques
Claudia Diniz Lopes Marques
ARAline Ranzolin
Aline Ranzolin
NCNara Gualberto Cavalcanti
Nara Gualberto Cavalcanti
ADAngela Luzia Branco Pinto Duarte
Angela Luzia Branco Pinto Duarte

1 January 2017 in Revista Brasileira de Reumatologia (English Edition)
Verified
Journal Article
Open access
CMClaudia Diniz Lopes Marques
Claudia Diniz Lopes Marques
ADAngela Luzia Branco Pinto Duarte
Angela Luzia Branco Pinto Duarte
ARAline Ranzolin
Aline Ranzolin
ADAndrea Tavares Dantas
Andrea Tavares Dantas
NCNara Gualberto Cavalcanti
Nara Gualberto Cavalcanti
GCGeorges Christopoulos
Georges Christopoulos
Chikungunya fever has become an important public health problem in countries where epidemics occur because half of the cases progress to chronic, persistent and debilitating arthritis. Literature data on specific therapies at the various phases of arthropathy caused by chikungunya virus (CHIKV) infection are limited, lacking quality randomized trials assessing the efficacies of different therapies. There are a few studies on the treatment of musculoskeletal manifestations of chikungunya fever, but these studies have important methodological limitations. The data currently available preclude conclusions favorable or contrary to specific therapies, or an adequate comparison between the different drugs used. The objective of this study was to develop recommendations for the treatment of chikungunya fever in Brazil. A literature review was performed via evidence-based selection of articles in the databases Medline, SciELO, PubMed and Embase and conference proceedings abstracts, in addition to expert opinions to support decision-making in defining recommendations. The Delphi method was used to define the degrees of agreement in 2 face-to-face meetings and several online voting rounds. This study is part 2 of the Recommendations of the Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia - SBR) for the Diagnosis and Treatment of chikungunya fever and specifically addresses treatment.